Azar Says J&J (JNJ) Vaccine Trial Setback Shouldn't Alter Timeline - Bloomberg
Tweet
Share
E-mail
Get Alerts JNJ Hot Sheet
Price: $275.77 +1.69%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2%
Revenue Growth %: +5.5%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2%
Revenue Growth %: +5.5%
Join SI Premium – FREE
Azar Says J&J (NYSE: JNJ) Vaccine Trial Setback Shouldn't Alter Timeline - Bloomberg
- Health Secretary Says Two Vaccine Trails Almost Enrolled
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3
- Intelligent Bio Solutions reports 98% accuracy in drug screening study
Create E-mail Alert Related Categories
FDA, PoliticsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
